Press Releases June 1, 2026 07:30 AM

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx announces participation in key investor conferences to engage with institutional investors and present corporate developments.

By Jordan Park OPRX

OptimizeRx Corp., a healthcare technology company specializing in AI-driven marketing solutions for life sciences, announced that its management will participate in prominent investor conferences including the Stifel 2026 Boston Cross Sector Conference and the 46th Annual William Blair Growth Stock Conference. The participation aims to showcase the company's innovations and growth strategies to institutional investors.

OptimizeRx to Participate in Upcoming Investor Conferences
OPRX

Key Points

  • OptimizeRx will engage in one-on-one investor meetings and presentations at major investment conferences in June 2026.
  • The company emphasizes its AI-driven healthcare solutions platform that connects life science brands with healthcare providers and patients for improved treatment outcomes.
  • Participation in these conferences demonstrates OptimizeRx’s efforts to increase visibility and attract investment in the healthcare technology sector.

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:

  • Stifel 2026 Boston Cross Sector 1x1 Conference, Boston, June 2 – 3, 2026
  • 46th Annual William Blair Growth Stock Conference, Chicago, June 2 – 4, 2026
Stifel 2026 Boston Cross Sector 1x1 ConferenceDate:  Tuesday, June 2, 2026 Format: 1x1 Meetings Location: InterContinental Boston   William Blair & Company’s 46th Annual Growth Stock ConferenceDate:  Wednesday, June 3, 2026 Format: 1x1 Meetings and Corporate PresentationLocation: Loews Hotel Chicago Presentation Time: 8-8:30 am CDT

To request a meeting or for more details about the conferences please reach out to your institutional contact.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. 

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
[email protected]

Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
[email protected]    


Risks

  • Market reception of the company’s platform and growth potential remains uncertain despite conference participation.
  • Competition in the healthcare technology and AI-driven marketing solutions space could impact future performance.
  • Regulatory changes and privacy concerns in healthcare data and marketing could pose challenges to OptimizeRx’s business model.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026